|
| Title |
Pub. Date |
Int. Class |
App. Num |
Applicant |
| 1. |
(WO 2006/072113) THERAPEUTIC COMPOSITION
|
06.07.2006
|
A61K 31/12
|
PCT/US2006/000052
|
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
|
| |
An anti-mitotic composition with a therapeutic index greater than 1.1 , a clonogenic survival rate of less than 0.1 percent, and a binding affinity index for a class II, a class III, or a class V beta tubulin isot e of at least about 1.1.
|
| |
|
| 2. |
(WO 2006/072112) UPFLOW MICROBIAL FUEL CELL (UMFC)
|
06.07.2006
|
H01M 8/16
|
PCT/US2005/047697
|
WASHINGTON UNIVERSITY
|
| |
An upflow microbial fuel cell in one embodiment is comprised of a generally cylindrical cathode chamber containing a cathode sitting atop a generally cylindrical anode chamber containing an anode, with a proton exchange membrane separating the two chambers, so that as influent is passed upwardly through the anode chamber electricity is created in a continuous process not requiring mixing such as with a mechanical mixer or the like. Electrodes are connected to each of the anode and the cathode for harvesting the electricity so created. Effluent may be recirculated through the anode chamber by a second inlet and outlet therein. A multiphase fuel cell includes a plurality of electrode couples arranged in a single chamber with an influent inlet...
|
| |
|
| 3. |
(WO 2006/072085) PURIFICATION OF CARBON NANOTUBES BASED ON THE CHEMISTRY OF FENTON'S REAGENT
|
06.07.2006
|
C01B 31/02
|
PCT/US2005/047634
|
WILLIAM MARSH RICE UNIVERSITY
|
| |
The present invention is directed to methods of purifying carbon nanotubes (CNTs). In general, such methods comprise the following steps: (a) preparing an aqueous slurry of impure CNT material; (b) establishing a source of Fe2+ ions in the slurry to provide a catalytic slurry; (c) adding hydrogen peroxide to the catalytic slurry to provide an oxidative slurry, wherein the Fe2+ ions catalyze the production of hydroxyl radicals; and (d) utilizing the hydroxyl radicals in the oxidative slurry to purify the CNT material and provide purified CNTs.
|
| |
|
| 4. |
(WO 2006/072075) GENETIC MARKERS OF SCHIZOPHRENIA
|
06.07.2006
|
C12P 19/34
|
PCT/US2005/047611
|
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
|
| |
The invention includes method of determining if a subject is at risk for developing schizophrenia (SZ), schizotypal personality disorder (SPD), or schizoaffective disorder (SD).
|
| |
|
| 5. |
(WO 2006/072048) COMPOSITIONS AND METHODS FOR IDENTIFYING MODULATORS OF HAUSP
|
06.07.2006
|
A61K 38/04
|
PCT/US2005/047572
|
THE TRUSTEES OF PRINCETON UNIVERSITY
|
| |
The disclosure relates to compositions and methods for modulating the biological activity of HAUSP protein. Among the activities that can be modulated are binding of HAUSP protein with proteins such as p53, MDM2, and EBNA1; modulation of HAUSP isopeptidase activity; and modulation of binding of HAUSP protein with ubiquitin and ubiquitinated proteins.
|
| |
|
| 6. |
(WO 2006/072029) APPARATUS AND METHOD FOR TREATING ULNAR NEUROPATHY
|
06.07.2006
|
A61F 13/00
|
PCT/US2005/047538
|
THE JOHNS HOPKINS UNIVERSITY
|
| |
An apparatus and method for treating ulnar neuropathy are disclosed An apparatus (40) for treating ulnar neuropathy includes an inne face (42) for engaging an arm with an upper end terminating above the elbow and a lower end terminating below the elbow, a plurality of mechanical fasteners (46) along an edge of the inner face (42). an outer face (44) having channels (54) to promote circumferential flexibility, and a plurality of mechanical fasteners on the outer face positioned to oppose the plurality of mechanical fasteners on the inner face A method of treating ulnar neuropathy includes placing an inner face in contact with the arm, wrapping the device (40) around the arm to extend above and below the elbow, engaging mechanical fasteners (...
|
| |
|
| 7. |
(WO 2006/072016) METHODS FOR REGULATION OF STEM CELLS
|
06.07.2006
|
C12Q 1/68
|
PCT/US2005/047508
|
UNIVERSITY OF WASHINGTON
|
| |
Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease by administering one or more Wnt/β-catenin signal-, Notch signal-, or Hedgehog signal- promoting agents to a mammalian subject in need thereof.
|
| |
|
| 8. |
(WO 2006/072005) METHODS FOR HIGH EFFICIENCY SURVIVAL/PROLIFERATION OF HUMAN EMBYONIC STEM CELLS AND HUMAN EMBYRO SURVIVAL IN CULTURE
|
06.07.2006
|
C12N 5/00
|
PCT/US2005/047481
|
THE JOHNS HOPKINS UNIVERSITY
|
| |
The present invention provides a role for neurotrophins in hES cell survival and important new insights into the molecular mechanisms controlling the growth of these cells. Although previous studies identified growth factors that affect self-renewal of hES cells, the novelty of the present invention is the identification of factors that act through specific receptors present on hES cells and activate the receptors at physiological concentrations to promote survival and proliferation.
|
| |
|
| 9. |
(WO 2006/071986) HIGH INTENSITY LASER OR DIODE-BASED LIGHTING APPARATUS HAVING INTEGRATED OPTICS
|
06.07.2006
|
G02B 6/00
|
PCT/US2005/047426
|
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
|
| |
A high intensity lighting apparatus (400) includes an outer housing (402); a curved support disk (414) having an array of diode or laser-based integrated light source (410) attached thereto disposed within the housing. Each of the light source (110) includes a tube (112) having a laser or diode chip (111) at one end of the tube. The tubes each have at least one concave shaped exit surface (113) on an end opposite the chip, wherein the concave exit surface converges light emitted from each of the light source to focal points within the housing (402). A shape of the curved support disk (414) converges the respective focal points into a light beam having a common focal plane (441). Adjustable secondary optics (431) are disposed in the housing ...
|
| |
|
| 10. |
(WO 2006/071970) METHODS FOR THE DETECTION OF ANALYTES IN A SAMPLE
|
06.07.2006
|
G01N 33/58
|
PCT/US2005/047381
|
GEORGETOWN UNIVERSITY
|
| |
A method for detecting the presence or concentration of an analyte in a sample, wherein: a) the sample is contacted with an immobilized first binding reagent which is capable of binding the analyte if present in the sample; b) the sample is contacted with a second binding reagent which comprises a fusion protein having a reporter domain and a binding domain, and which is capable of binding the analyte if present in the sample, the first and second binding reagents being capable of binding the analyte simultaneously if present in the sample, such that said second binding reagent becomes immobilized through the analyte bound to the first binding reagent; and detecting whether the second binding reagent has become immobilized to thereby detect...
|
| |
|
| 11. |
(WO 2006/071902) AN IN-HIVE TRAP AND ATTRACTANT COMPOSITION FOR THE CONTROL OF THE SMALL HIVE BEETLE, AETHINA TUMIDA
|
06.07.2006
|
A01K 47/06
|
PCT/US2005/047152
|
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
|
| |
A Small Hive Beetle trap, which replaces the bottom board of beehives, includes a frame having three walls and a top surface, a trap plate, an entry means, and a trapping means. The trapping means provides a dark environment attractive to small hive beetles and contains a small hive beetle attractant made from pollen dough and inoculated with yeast that produces small hive beetle attracting volatiles.
|
| |
|
| 12. |
(WO 2006/071896) EPITOPE-BASED SARS VACCINE
|
06.07.2006
|
C12N 15/50
|
PCT/US2005/047144
|
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
|
| |
This invention provides a vaccine for the infectious severe acute respiratory syndrome (SARS), which comprises antigenic epitopes from the pathogenic coronavirus. The antigenic epitopes were determined from the complementary antibodies in the plasma of convalescent SARS patients through phage display epitope mapping. These immunodominants consit of short peptide fragments distributed on various viral proteins, which includes, the spike protein, the nucleocapsid protein, the replicase 1a, and the unknown proteins 3a and 9b. Complementary antibodies targeting the immunodominant site on the spike protein effectively neutralize the coronavirus in vitro. This epitope-based vaccine avoids potential immunopathologic effects found in vaccines for o...
|
| |
|
| 13. |
(WO 2006/071884) OLIGONUCLEOTIDE BASED THERAPEUTICS
|
06.07.2006
|
C07H 21/02
|
PCT/US2005/047119
|
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
|
| |
The present invention relates to compositions comprising dsRNA. In particular, the present invention provides dsRNA comprising nucleotide sequence that is selectively complementary to bcl-xL mRNA sequence and that is not selectively complementary to bcl-xS mRNA sequence, recombinant nucleic acid comprising a vector and nucleic acid sequence for expressing bcl-xL dsRNA, pharmaceutical compositions comprising bcl-xL dsRNA, kits comprising such compositions, and methods of using the same in research, therapeutic, diagnostic and/or drug screening applications.
|
| |
|
| 14. |
(WO 2006/071864) COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF VAGINAL INFECTIONS
|
06.07.2006
|
A01N 63/00
|
PCT/US2005/047074
|
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
|
| |
Applicants have discovered that a particular bacteriocin from the vaginal strain of Lactobacillus rhamnosus, lactocin (160), possesses a particularly advantageous activity against microorganisms associated with vaginal infections, and more specifically those associated with Bacterial Vaginosis (BV). Specifically, this compound is an effective and non-cytotoxic antibacterial agent that provides the basis for formulations for the improved prophylaxis and treatment of vaginal infections, and attendant reduction in the acquisition and proliferation of HIV. Applicants have isolated and purified the antimicrobial peptide lactocin (160) from a vaginal strain of L. rhamnosus. The peptide shows antibacterial activity in an agar-well bioassay against...
|
| |
|
| 15. |
(WO 2006/071861) MULTI-PIXEL ELECTRON MICROBEAM IRRADIATOR SYSTEMS AND METHODS FOR SELECTIVELY IRRADIATING PREDETERMINED LOCATIONS
|
06.07.2006
|
H01J 1/02
|
PCT/US2005/047066
|
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
|
| |
Multi-pixel electron microbeam irradiator systems and methods are provided with particular applicability for selectively irradiating predetermined cells or cell locations. A multi-pixel electron microbeam irradiator system can include a plurality of individually addressable electron field emitters sealed in a vacuum. The multi-pixel electron microbeam irradiator system can include an anode comprising one or more electron permeable portions corresponding to the plurality of electron field emitters. Further, the multi-pixel electron microbeam irradiator system can include a controller operable to individually control electron extraction from each of the electron field emitters for selectively irradiating predetermined locations such as cells ...
|
| |
|
| 16. |
(WO 2006/071848) GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS
|
06.07.2006
|
A61K 31/70
|
PCT/US2005/047017
|
THE ROCKEFELLER UNIVERSITY
|
| |
This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
|
| |
|
| 17. |
(WO 2006/071822) EXOTOXIN INHIBITORY FACTOR
|
06.07.2006
|
C07K 14/435
|
PCT/US2005/046948
|
REGENTS OF THE UNIVERSITY OF MINNESOTA
|
| |
The invention provides an exotoxin inhibitory factor, compositions containing the factor, methods of using the compositions.
|
| |
|
| 18. |
(WO 2006/071805) PERINUCLEOLAR COMPARTMENT MARKERS FOR CANCERS
|
06.07.2006
|
C12Q 1/68
|
PCT/US2005/046890
|
NORTHWESTERN UNIVERSITY
|
| |
The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers.
|
| |
|
| 19. |
(WO 2006/071769) CONTROLLED RELEASE FROM BLOCK CO-POLYMER WORM MICELLES
|
06.07.2006
|
A61K 9/10
|
PCT/US2005/046770
|
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
|
| |
Provided is a method of controlling the release of at least one encapsulated active agent from a worm-like micelle, wherein each worm-like micelle comprises one or more amphiphilic block copolymers that self assemble in aqueous solution, without organic solvent or post assembly polymerization; wherein at least one of said amphiphilic molecules is a hydrophilic block copolymer and at least one of said amphiphilic molecules is a hydrophobic block copolymer which is hydrolyticaly unstable in the pH range of about 5 to about 7. The loaded worm-like micelles of the present invention are particularly suited for the stable and controlled transport, delivery and storage of materials, either in vivo or in vitro.
|
| |
|
| 20. |
(WO 2006/071659) DELIVERY OF H2 ANTAGONISTS
|
06.07.2006
|
A61K 31/4164
|
PCT/US2005/046280
|
TRUSTEES OF BOSTON UNIVERSITY
|
| |
The present invention provides improved systems and methods for the local delivery of H2 antagonists. The inventive methods include topical administration of an effective amount of a H2 antagonist encapsulated in liposomes. In certain embodiments, the H2 antagonist, for example, Cimetidine, is encapsulated into paucilamellar liposomes, such as NOVASOME® microvesicles. Also provided are pharmaceutical compositions comprising liposome-encapsulated H2 antagonists. The methods and compositions of the present invention may be used to treat any disease state or condition where local administration of H2 antagonists is beneficial.
|
| |
|
| 21. |
(WO 2006/071642) CAVITY RING-DOWN DETECTION OF SURFACE PLASMON RESONANCE IN AN OPTICAL FIBER RESONATOR
|
06.07.2006
|
G01N 21/55
|
PCT/US2005/046160
|
TRUSTEES OF PRINCETON UNIVERSITY
|
| |
An apparatus and method for use with a coherent optical source to detect environmental changes. The apparatus comprises: an optical cavity, including an input coupling port, and an optical fiber section; a detector optically coupled to the optical cavity to monitor radiation in the optical cavity; and a processor electrically coupled to the detector for analyzing the environmental changes adjacent the detection portion of the optical cavity based on a rate of decay of the radiation in the optical cavity monitored by the detector. The optical fiber section of the optical cavity includes a detection portion coated with a conductive layer capable of supporting a surface plasmon to provide cavity loss. The surface plasmon is responsive to the e...
|
| |
|
| 22. |
(WO 2006/071640) PHOTOLYTIC POLYMER SURFACE MODIFICATION
|
06.07.2006
|
C08F 20/02
|
PCT/US2005/046147
|
THE REGENTS OF THE UNIVERSITY OF COLORADO
|
| |
The present invention provides a method for modifying a surface of a polymer derived from a mixture comprising a thiol monomer and an olefinic monomer. The method comprises exposing at least a portion of the polymer surface to electromagnetic radiation of sufficient energy to modify the polymer surface. The present invention also provides a polymer derived from polymerizing a mixture of monomers comprising a thiol monomer, an olefinic monomer, and an iniferter.
|
| |
|
| 23. |
(WO 2006/071603) PHOSPHODIESTERASE 4D IN THE RYANODINE RECEPTOR COMPLEX PROTECTS AGAINST HEART FAILURE
|
06.07.2006
|
C12N 9/16
|
PCT/US2005/045914
|
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
|
| |
The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cell...
|
| |
|
| 24. |
(WO 2006/071543) HIGH RATE BUFFER LAYER FOR IBAD MgO COATED CONDUCTORS
|
06.07.2006
|
B32B 9/00
|
PCT/US2005/045347
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
Articles are provided including a base substrate having a layer of an oriented material thereon, and, a layer of hafnium oxide upon the layer of an oriented material. The layer of hafnium oxide can further include a secondary oxide such as cerium oxide, yttrium oxide, lanthanum oxide, scandium oxide, calcium oxide and magnesium oxide. Such articles can further include thin films of high temperature superconductive oxides such as YBCO upon the layer of hafnium oxide or layer of hafnium oxide and secondary oxide.
|
| |
|
| 25. |
(WO 2006/071542) ARCHITECTURE FOR COATED CONDUCTORS
|
06.07.2006
|
H01F 6/00
|
PCT/US2005/045345
|
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
|
| |
Articles are provided including a base substrate having a layer of an oriented cubic oxide material with a rock-salt-like structure layer thereon, and, a layer of epitaxial titanium nitride upon the layer of an oriented cubic oxide material having a rock-salt-like structure. Such articles can further include thin films of high temperature superconductive oxides such as YBCO upon the layer of epitaxial titanium nitride or upon a intermediate buffer layer upon the layer of epitaxial titanium nitride.
|
| |
|
![[Back to Top]](/ipdl/include/backtop.gif){kind=small}
